ClinicalTrials.gg
CompletedNCT00839852Updated Aug 22, 2019Results posted

A Study of Cariprazine in Patients With Chronic Stable Schizophrenia

A Phase 2 interventional study of Cariprazine in Schizophrenia, sponsored by Forest Laboratories. Completed at 65 sites in 5 countries. Open to participants aged 18 Years to 61 Years. Per ClinicalTrials.gov, last updated 2019-08-22.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
97
Allocation
Not applicable
Ages
18 Years to 61 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.

Enrollment
15th of 23
97 · median 129
Started
2009
the only one that year
Phase 2
4 of 23
none open now
Registered
3rd of 23
by date
Lead sponsor
8 of 23
Forest Laboratories

Among the 23 studies testing cariprazine in Schizophrenia, this one is the 15th largest by enrollment, is the only one that started in 2009, is one of 4 in phase 2, and was the 3rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cariprazine

cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 61 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cariprazine in Schizophrenia, or all of them as a file.
02

Study summary

This is an outpatient study to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 61 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have completed the double-blind treatment period of the lead-in study RGH-MD-16 (NCT 00694707)
  • Patients who have responded to double-blind treatment in the lead-in study as defined as ≥ 20% reduction relative to Visit 2 (Baseline) of the Positive and Negative Syndrome Scale (PANSS) total score and a Clinical Global Impressions-Severity (CGI-S) score of ≤ 3.
  • Patients eligible to continue as outpatients based on the opinion of the Principal Investigator.
  • Patients must have a caregiver to ensure treatment compliance.

Exclusion criteria

Exclusion Criteria:

  • Patients with abnormalities on physical examination, laboratory, vital signs, and/or (ECG).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Cariprazine 1.5mg

    Participants received cariprazine 1.5 mg capsule once, twice or three times a day depending on their response and tolerability

    Drug: Cariprazine

Interventions

  • Cariprazine was supplied in capsules.

    Also known as: RGH-188

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 48 in the PANSS Total Score

    The Positive and Negative Syndrome Scale (PANSS) is a 30-item rating scale that assesses the positive and negative symptoms of individuals with schizophrenia. Responses to the 30 items are based on a structured clinical interview with the patient and on supporting clinical information obtained from family, hospital staff, or other reliable informants. Of the 30 psychiatric parameters measured by the scale, 7 assess positive symptoms (eg, delusions, grandiosity); 7 assess negative symptoms (eg, blunted affect, emotional withdrawal); and 16 assess general psychopathology (eg, poor attention, active social avoidance). Each item is scored on a 7-point scale (1 = absent, 2 = minimal, 3 = mild, 4 = moderate, 5 = moderately severe, 6 = severe, and 7 = extreme). The PANSS total score can range from 30 to 210. A higher score indicates worse symptoms. A negative change score indicates improvement.

    Time frame: Baseline to Week 48

Secondary outcomes

  1. Change From Baseline to Week 48 in the CGI-S Score

    The Clinical Global Impressions-Severity (CGI-S) scale is a 7-point scale that measures the overall severity of the illness compared with the severity of illness in other patients the Investigator has observed. The Investigator assesses the severity of the patient's illness as one of the following: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patients. The CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change score indicates improvement.

    Time frame: Baseline to Week 48

07

Results

Posted Aug 22, 2019

Participant flow

The Enrolled Population consisted of 97 participants who completed the lead-in study, RGH-MD-16, and signed an informed consent form to continue in this extension study. The Safety Population consisted of 93 participants from the Enrolled Population who took at least 1 dose of cariprazine in this extension study.

Participant flow — Overall Study
MilestoneCariprazine
Started93
Completed46
Not completed47
Withdrew: Adverse event10
Withdrew: Insufficient therapeutic response3
Withdrew: Protocol violation9
Withdrew: Withdrawal of consent16
Withdrew: Lost to follow-up7
Withdrew: Lack of compliance while in jail1
Withdrew: Pregnancy1

Outcome measures

PrimaryChange From Baseline to Week 48 in the PANSS Total Score

The Positive and Negative Syndrome Scale (PANSS) is a 30-item rating scale that assesses the positive and negative symptoms of individuals with schizophrenia. Responses to the 30 items are based on a structured clinical interview with the patient and on supporting clinical information obtained from family, hospital staff, or other reliable informants. Of the 30 psychiatric parameters measured by the scale, 7 assess positive symptoms (eg, delusions, grandiosity); 7 assess negative symptoms (eg, blunted affect, emotional withdrawal); and 16 assess general psychopathology (eg, poor attention, active social avoidance). Each item is scored on a 7-point scale (1 = absent, 2 = minimal, 3 = mild, 4 = moderate, 5 = moderately severe, 6 = severe, and 7 = extreme). The PANSS total score can range from 30 to 210. A higher score indicates worse symptoms. A negative change score indicates improvement.

Time frame:
Baseline to Week 48
Reported as:
Mean · Units on a scale
Change From Baseline to Week 48 in the PANSS Total Score
Units on a scaleCariprazine
Change From Baseline to Week 48 in the PANSS Total Score-38.5 ± 1.5
SecondaryChange From Baseline to Week 48 in the CGI-S Score

The Clinical Global Impressions-Severity (CGI-S) scale is a 7-point scale that measures the overall severity of the illness compared with the severity of illness in other patients the Investigator has observed. The Investigator assesses the severity of the patient's illness as one of the following: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patients. The CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change score indicates improvement.

Time frame:
Baseline to Week 48
Reported as:
Mean · Units on a scale
Change From Baseline to Week 48 in the CGI-S Score
Units on a scaleCariprazine
Change From Baseline to Week 48 in the CGI-S Score-2.0 ± 0.1

Adverse events

Collected over Baseline to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cariprazine0/93 (0%)12/93 (12.9%)62/93 (66.7%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventCariprazine
SchizophreniaPsychiatric disorders4/93
Psychotic disorderPsychiatric disorders2/93
Adjustment disorderRenal and urinary disorders1/93
AgitationPsychiatric disorders1/93
Completed suicidePsychiatric disorders1/93
AsthmaRespiratory, thoracic and mediastinal disorders1/93
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/93
Social stay hospitalisationSocial circumstances1/93
Haemorrhoidal haemorrhageGastrointestinal disorders1/93
FilariasisInfections and infestations1/93
Most frequent other events
Showing 10 of 17
Most frequent other events
EventCariprazine
AkathisiaNervous system disorders13/93
InsomniaPsychiatric disorders13/93
Weight increasedInvestigations11/93
NasopharyngitisInfections and infestations8/93
HeadacheNervous system disorders8/93
DizzinessNervous system disorders7/93
TremorNervous system disorders7/93
AgitationPsychiatric disorders7/93
AnxietyPsychiatric disorders7/93
Extrapyramidal disorderNervous system disorders6/93

Baseline characteristics

Safety population: All enrolled participants who took at least 1 dose of cariprazine.

Age, Continuous
Age, Continuous(years)Cariprazine
Mean34.4 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Cariprazine
Female30
Male63
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cariprazine
Hispanic or Latino5
Not Hispanic or Latino88
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cariprazine
American Indian or Alaska Native0
Asian30
Native Hawaiian or Other Pacific Islander0
Black or African American11
White52
More than one race0
Unknown or Not Reported0
Weight
Weight(kg)Cariprazine
Mean72.19 ± 17.66
Height
Height(cm)Cariprazine
Mean169.09 ± 10.73
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Cariprazine
Mean24.99 ± 4.46
Waist circumference
Waist circumference(cm)Cariprazine
Mean84.90 ± 11.19
08

Study locations

65 sites
  • Forest Investigative Site
    Costa Mesa, California 92626, United States
  • Forest Investigative Site
    Long Beach, California 90813, United States
  • Forest Investigative Site
    Oceanside, California 92056, United States
  • Forest Investigative Site
    Paramount, California 90723, United States
  • Forest Investigative Site
    Riverside, California 92506, United States
  • Forest Investigative Site
    Washington, District of Columbia 20016, United States
  • Forest Investigative Site
    Bradenton, Florida 34208, United States
  • Forest Investigative Site
    Kissimmee, Florida 34741, United States
  • Forest Investigative Site
    Lake Charles, Louisiana 70601, United States
  • Forest Investigative Site
    Baltimore, Maryland 21202, United States
  • Forest Investigative Site
    Flowood, Mississippi 39232, United States
  • Forest Investigative Site
    Creve Coeur, Missouri 63141, United States
  • Forest Investigative Site
    Cincinnati, Ohio 45267, United States
  • Forest Investigative Site
    Charleston, South Carolina 29405, United States
  • Forest Investigative Site
    Memphis, Tennessee 38119, United States
  • Forest Investigative Site
    Houston, Texas 77008, United States
  • Forest Investigative Site
    Irving, Texas 75062, United States
  • Forest Investigative Site
    Vijaywada, Andh Prad 520002, India
  • Forest Investigative Site
    Visakhapatnam, Andh Prad 530017, India
  • Forest Investigative Site
    Ahmedabad, Gujarat 380013, India
  • Forest Investigative Site
    Ahmedabad, Gujarat 380015, India
  • Forest Investigative Site
    Bangalore, Karna 560010, India
  • Forest Investigative Site
    Bangalore, Karna 560027, India
  • Forest Investigative Site
    Mangalore, Karna 574160, India
  • Forest Investigative Site
    Mangalore, Karna 575001, India
  • Forest Investigative Site
    Manipal, Karna 576104, India
  • Forest Investigative Site
    Mysore, Karna 570004, India
  • Forest Investigative Site
    Pune, Mahara 411004, India
  • Forest Investigative Site
    Jaipur, Rajasthan 302021, India
  • Forest Investigative Site
    Chennai, Tamilnadu 600003, India
  • Forest Investigative Site
    Chennai, Tamilnadu 600101, India
  • Forest Investigative Site
    Tirupati, Tamilnadu 517507, India
  • Forest Investigative Site
    Kanpur, Uttar Prad 208005, India
  • Forest Investigative Site
    Johor Bahru, 80100, Malaysia
  • Forest Investigative Site
    Kuala Lumpur, 59100, Malaysia
  • Forest Investigative Site
    Perak, 30990, Malaysia
  • Forest Investigative Site
    Arkhangelsk, 163060, Russian Federation
  • Forest Investigative Site
    Gatchina, 188357, Russian Federation
  • Forest Investigative Site
    Ivanovo, 153462, Russian Federation
  • Forest Investigative Site
    Kazan, 420012, Russian Federation
  • Forest Investigative Site
    Krasnodar, 350007, Russian Federation
  • Forest Investigative Site 204
    Moscow, 115522, Russian Federation
  • Forest Investigative Site 206
    Moscow, 115522, Russian Federation
  • Forest Investigative Site
    Moscow, 117152, Russian Federation
  • Forest Investigative Site
    Nizhniy Novgorod, 603155, Russian Federation
  • Forest Investigative Site
    Samara, 443016, Russian Federation
  • Forest Investigative Site 214
    St. Petersburg, 190005, Russian Federation
  • Forest Investigative Site 217
    St. Petersburg, 190005, Russian Federation
  • Forest Investigative Site
    St. Petersburg, 190121, Russian Federation
  • Forest Investigative Site
    St. Petersburg, 191119, Russian Federation
  • Forest Investigative Site 202
    St. Petersburg, 193019, Russian Federation
  • Forest Investigative Site 203
    St. Petersburg, 193019, Russian Federation
  • Forest Investigative Site
    St. Petersburg, 193167, Russian Federation
  • Forest Investigative Site
    St. Petersburg, 197341, Russian Federation
  • Forest Investigative Site
    Kherson, Vil. Stepanivka 73488, Ukraine
  • Forest Investigative Site
    Chernigov, 14000, Ukraine
  • Forest Investigative Site
    Dnipropetrovsk, 49616, Ukraine
  • Forest Investigative Site
    Donetsk, 83037, Ukraine
  • Forest Investigative Site
    Glevakha, 8630, Ukraine
  • Forest Investivative Site
    Kharkiv, 61068, Ukraine
  • Forest Investigative Site
    Kiev, 2660, Ukraine
  • Forest Investigative Site
    Kyiv, 4080, Ukraine
  • Forest Investigative Site
    Kyiv, 4655, Ukraine
  • Forest Investigative Site
    Odessa, 65006, Ukraine
  • Forest Investigative Site
    Ternopil, 46020, Ukraine
09

References and documents

Publications

  • Laszlovszky I, Barabassy A, Nemeth G. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Adv Ther. 2021 Jul;38(7):3652-3673. doi: 10.1007/s12325-021-01797-5. Epub 2021 Jun 6. PubMed 34091867 ↗
  • Barabassy A, Sebe B, Acsai K, Laszlovszky I, Szatmari B, Earley WR, Nemeth G. Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies. Neuropsychiatr Dis Treat. 2021 Apr 7;17:957-970. doi: 10.2147/NDT.S301225. eCollection 2021. Erratum In: Neuropsychiatr Dis Treat. 2021 May 17;17:1481. doi: 10.2147/NDT.S316858. PubMed 33854317 ↗
  • Nasrallah HA, Earley W, Cutler AJ, Wang Y, Lu K, Laszlovszky I, Nemeth G, Durgam S. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry. 2017 Aug 24;17(1):305. doi: 10.1186/s12888-017-1459-z. PubMed 28836957 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2009 to primary completion in Aug 2010, 15 months.

Results were first posted in Aug 2019, 8 years 11 months after primary completion. A results delay was requested in Sep 2011.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 15 months is below that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2009
First posted
Feb 10, 2009
StartActual
May 31, 2009
Primary completionActual
Aug 31, 2010
CompletionActual
Aug 31, 2010
Results delay requested
Sep 13, 2011
Results first posted
Aug 22, 2019
Last update
Aug 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00839852
Collaborators
Gedeon Richter Ltd.
Responsible party
Sponsor
First posted
Feb 10, 2009
Start date
May 31, 2009
Primary completion
Aug 31, 2010
Completion
Aug 31, 2010
Results posted
Aug 22, 2019
Last update
Aug 22, 2019

Study contacts

Suresh Durgam, MD
study director · Forest Research Institute, a subsidiary of Forest Laboratories, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion